Becker's Healthcare June 6, 2024
An FDA committee voted unanimously June 5 on the 2024-2025 COVID-19 vaccine makeup, recommending it should be one that targets the monovalent JN.1-lineage.
Jerry Weir, PhD, director of the FDA’s division of viral products’ office of vaccines research and review, said before the vote that “JN.1 has continued to evolve, and it makes it somewhat difficult to pick the specific string to be used” for the composition of the next fall COVID vaccine.
JN.1 emerged in September 2023 and by late December accounted for a majority of circulating COVID-19 infections in the U.S.
Following the vote, the Vaccines and Related Biological Products Advisory Committee also discussed whether the new vaccines should target a specific sub-lineage of JN.1, such as the...
Today's Sponsors
Today's Sponsor